Definium Therapeutics

The Phase‑3 Voyage study showed that DT120 ODT (pharmaceutically optimized LSD formulation) met the primary endpoint and all key secondary endpoints in generalized anxiety disorder, with a statistically significant reduction in HAM‑A score and a higher response rate versus placebo. Treatment was generally well tolerated; adverse events were mild to moderate and mostly occurred on the day of dosing. This is the second positive Phase‑3 readout following the Emerge depression results; further Panorama data are expected in September 2026. According to the company, Definium holds roughly $1.1 billion in cash and views its financing as secured through 2030. » More on finanzen.net

Definium Therapeutics' stock last traded near its 52-week high of $47.01 and is currently at $47.20, after rising 613.41% over the past year. The company raised $805 million via a guaranteed capital increase (sale of 23,676,471 common shares at $34.00), and plans a separate offering of common shares and pre-funded warrants totaling $500 million. Needham raised its price target to $50.00 and reiterated a "Buy" rating following promising EMERGE data for treating major depression, while InvestingPro warns of potential overvaluation and high volatility (beta 2.38). » More on de.investing.com

Definium Therapeutics presented results for the quarter ended March 31, 2026, reporting a loss of 0.71 USD per share, after -0.35 USD in the year-ago quarter. The results were presented on May 7, 2026 at a financial conference. » More on finanzen.net